Ciba-Geigy Corp. v. Alza Corp.

804 F. Supp. 614, 23 Fed. R. Serv. 3d 1246, 26 U.S.P.Q. 2d (BNA) 1321, 1992 U.S. Dist. LEXIS 16395, 1992 WL 301634
District Court, D. New Jersey·Decided October 23, 1992·No. Civ. A. 91-5286·Published·Cited by 22 cases

Opinion

OPINION

WOLIN, District Judge.

Before the Court is the motion by counterclaim-defendant, the Regents of the University of California (the “Regents”), to dismiss the counterclaim filed against it by defendants on the basis of sovereign immunity pursuant to the Eleventh Amendment. Additionally, before the Court is the motion of defendants, Alza Corporation (“Alza”) and Marrion Merrell Dow Inc. (“Marrion Merrell Dow”) (collectively “defendants”) to dismiss the complaint on the ground that plaintiff, Ciba-Geigy corporation (“Ciba-Geigy”), has no standing to institute the present lawsuit. For the reasons expressed below, this Court will grant the Regent’s motion to dismiss defendants’ counterclaim under the Eleventh Amendment and will deny defendants’ motion to dismiss the complaint for lack of standing.

BACKGROUND

Ciba-Geigy commenced the present action against defendants for infringing the 5,016,652 patent (the “ ’652 patent”). Ciba-Geigy produces HABITROL under the ’652 patent, a nicotine patch that helps people to cease smoking. It claims that defendants’ NICODERM product, a nicotine patch employed to aid people to stop smoking, infringes the ’652 patent.

Drs. Murray Jarvick, Karce Rose, and Jed Rose are the inventors of the ’652 patent. The Veterans Administration (the “V.A.”), and the Regents employed Drs. Murray Jarvick and Jed Rose while they were developing the ’652 patent. Dr. Karce Rose was in private practice. Declaration of Jed E. Rose, Ph.D. (“Rose Dec.”) ¶ 3.

The Regents contacted the V.A. about the V.A.’s interest in Drs. Rose’s and Jar-vick’s inventions. Some of these inventions were disclosed in the ’652 patent. In its correspondence with the V.A., the Regents suggested that the V.A. assign its rights in the inventions to its employees, the inventors. The Regents stated its intent to license the inventions. Moreover, the Regents acknowledged its obligation to administer the inventions in accordance with P.L. 98-620 (the 1984 amendment to 35 U.S.C. § 202).

The Regents noted that neither the “Transdermal Administration of Nicotine as a Cessation Smoking Aid” nor the “Method and Apparatus for Aiding in the Reduction of Incidence of Tobacco Smoking” were invented with any grant from the National Institutes of Health. The preceding inventions formed the ’652 patent.

Drs. Jarvick and Karce Rose disclosed to the V.A. that they had produced the inventions (that were later described in the ’652 patent) during the time that the V.A. em *617 ployed them. Specifically, Drs. Jarvick and Karce Rose informed the V.A. that they developed the ’652 patent using the V.A.’s facilities, during working hours, and using the V.A.’s equipment. Rose Dec. H 4-5, Exhs. A, B. The V.A. decided that it had made an insignificant contribution to the '652 patent’s development, and disclaimed any right it had to the invention. Accordingly, pursuant to 37 C.F.R. § 100.-6(b)(2) (now codified at 38 C.F.R. § 1.650 et seq.), the V.A. ceded any interest that it had in the invention to its inventors subject to a “nonexclusive irrevocable, royalty free license in the invention with power to grant licenses for all governmental purposes.” Rose Dec. 11 9, Exh. C. Subsequently, the inventors assigned all of their rights to the ’652 patent to the Regents. Rose Dec. 1110, Exh. D.

Although the Regents did not receive any grant from the NIH to help it develop the inventions underlying the ’652 patent, the University of California received a, $4,942 Biomedical Research Support Grant from the Department of Health and Human Services to develop what became the ’652 patent, Rose Dec. Exh. B, and a grant from the National Institute of Drug Abuse. Supplemental Declaration of Theresa M. Gillis (“Gillis Supp. Dec.”) Exhs. 2-4. No party has produced any evidence to indicate whether the Department of Health and Human Services or the National Institute of Drug Abuse claims any interest in the ’652 patent. The patent application discloses that these two agencies contributed to the patent.

The Regents gave Ciba-Geigy an option for an exclusive license to the ’652 patent on June 2, 1988. 1 The original option expired on May 31, 1990. Declaration- of Theresa M. Gillis (“Gillis Dec.”) Exh. E. The Regents extended the option until May 31, 1992. Gillis Dec. Exh. F.

On October 29, 1991, the Regents and Ciba-Geigy entered into an exclusive licensing agreement. Pursuant to that agreement, Ciba-Geigy agreed to comply with 35 U.S.C. §§ 200-204 2 . Exclusive License Agreement § 23. These sections require an entity to “substantial manufacture” its products in the United States. 35 U.S.C. § 204. Additionally, Ciba-Geigy agreed to “reasonably fill the market demand for [the] licensed product.” Exclusive License Agreement Article 6.1.

If Ciba-Geigy fails to meet these conditions, the Exclusive License agreement allows the Regents to send a written notice of default to Ciba-Geigy. The Exclusive License Agreement provides further that if Ciba-Geigy fails to cure the default “or to demonstrate that it made reasonable efforts to cure the default” then the Regents can terminate Ciba-Geigy’s exclusive license. Exclusive License Agreement Articles 6.4, 9.1. Furthermore, the Regents retained certain rights concerning the patent under the Exclusive License Agreement. For example, the Regents retained a right to use the patent for “educational and research purpose.” Exclusive License Agreement Article 2.3. Additionally, the Exclusive License Agreement allows Ciba-Geigy to assign the contract only with the Regents’ consent. The License Agreement provides that the Regents must consent to a reasonable assignment. Exclusive License Agreement Article 18.1. The Exclusive License Agreement permits Ciba-Gei-gy to sub-license the patent, however, without obtaining the Regents’ consent.

Finally, the License Agreement forces Ciba-Geigy to confer with the Regents before Ciba-Geigy would institute any action for patent infringement. The License Agreement prohibits Ciba-Geigy from commencing a lawsuit within five days of notifying the Regents of the alleged infringe *618 ment without first obtaining the Regents’ consent. Under the License Agreement, the Regents agreed to act as a nominal plaintiff, if it was required for Ciba-Geigy to bring an infringement action. License Agreement 15.2. Moreover, pursuant to Article 15.4 of the License Agreement, the Regents retained the right to bring its own action for patent infringement or to join a lawsuit brought by Ciba-Geigy.

After Ciba-Geigy began this action but prior to the defendants instituting their counterclaim against the Regents, Ciba-Geigy and the Regents amended Article 15 of the License Agreement.

Free access — add to your briefcase to read the full text and ask questions with AI

Ciba-Geigy Corp. v. Alza Corp., 804 F. Supp. 614, 23 Fed. R. Serv. 3d 1246, 26 U.S.P.Q. 2d (BNA) 1321, 1992 U.S. Dist. LEXIS 16395, 1992 WL 301634 (D.N.J. 1992).

804 F. Supp. 614 (Ciba-Geigy Corp. v. Alza Corp.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Hochendoner v. Genzyme Corp.
95 F. Supp. 3d 15 (D. Massachusetts, 2015)
Trendx Enterprises, Inc. v. All-luminum Products, Inc.
856 F. Supp. 2d 661 (D. New Jersey, 2012)
IndyMac Bank v. Miguel
184 P.3d 821 (Hawaii Intermediate Court of Appeals, 2008)
Madey v. Duke University
413 F. Supp. 2d 601 (M.D. North Carolina, 2006)
Fenn v. Yale University
393 F. Supp. 2d 133 (D. Connecticut, 2004)
Transfair International, Inc. v. United States
54 Fed. Cl. 78 (Federal Claims, 2002)
Sunrise Medical HHG, Inc. v. AirSep Corp.
95 F. Supp. 2d 348 (W.D. Pennsylvania, 2000)
In Re Raphael
230 B.R. 657 (D. New Jersey, 1999)
Daniel v. American Board of Emergency Medicine
988 F. Supp. 127 (W.D. New York, 1997)
Procter & Gamble Co. v. Paragon Trade Brands, Inc.
917 F. Supp. 305 (D. Delaware, 1995)
Ciba-Geigy Corp. v. Alza Corp.
864 F. Supp. 429 (D. New Jersey, 1994)
Valmet Paper MacHinery, Inc. v. Beloit Corp.
868 F. Supp. 1085 (W.D. Wisconsin, 1994)
McNeilab, Inc. v. Scandipharm, Inc.
862 F. Supp. 1351 (E.D. Pennsylvania, 1994)
Gen-Probe Inc. v. Center for Neurologic Study
853 F. Supp. 1215 (S.D. California, 1993)